[Pneumology. Treatment of idiopathic pulmonary fibrosis: hopes and disappointment]. / Pneumologie. Traitement de la fibrose pulmonaire idiopathique: un espoir après une désillusion.
Rev Med Suisse
; 1(2): 153-4, 156-8, 2005 Jan 12.
Article
en Fr
| MEDLINE
| ID: mdl-15773218
Idiopathic pulmonary fibrosis (IPF) is now recognized as a separate nosological entity. Despite the progresses in understanding the basic mechanisms of the disease, its prognosis remains poor. The classical treatment combines prednisone with a cytotoxic agent. Interferon gamma has the in vitro capacity of inhibiting fibroblasts proliferation. A pilot study showed positive results, but a more recent randomized double blind trial was unable to demonstrate a clear benefit to the patients. On the other hand there are many evidences for an oxydant-antioxydant imbalance in the pathogenesis of IPF. In a human controlled study N-acetylcysteine (NAC) at high doses (1800 mg per day orally) improved the pulmonary function tests when given on top of a combined therapy with prednisone and azathioprine.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fibrosis Pulmonar
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
Fr
Revista:
Rev Med Suisse
Asunto de la revista:
MEDICINA
Año:
2005
Tipo del documento:
Article
Pais de publicación:
Suiza